InfuSystem (NYSE:INFU – Get Free Report) is one of 233 public companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its rivals? We will compare InfuSystem to similar businesses based on the strength of its institutional ownership, earnings, profitability, risk, dividends, valuation and analyst recommendations.
Earnings and Valuation
This table compares InfuSystem and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| InfuSystem | $144.44 million | $870,000.00 | 32.71 |
| InfuSystem Competitors | $21.22 billion | $301.67 million | -1.76 |
InfuSystem’s rivals have higher revenue and earnings than InfuSystem. InfuSystem is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares InfuSystem and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InfuSystem | 1.12% | 2.78% | 1.41% |
| InfuSystem Competitors | -7.86% | -135.41% | -1.59% |
Insider and Institutional Ownership
71.1% of InfuSystem shares are held by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 10.8% of InfuSystem shares are held by insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current recommendations for InfuSystem and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InfuSystem | 0 | 0 | 2 | 0 | 3.00 |
| InfuSystem Competitors | 1877 | 7751 | 13384 | 833 | 2.55 |
InfuSystem presently has a consensus target price of $17.50, suggesting a potential upside of 18.89%. As a group, “Healthcare Providers & Services” companies have a potential upside of 13.46%. Given InfuSystem’s stronger consensus rating and higher probable upside, equities analysts plainly believe InfuSystem is more favorable than its rivals.
Risk & Volatility
InfuSystem has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, InfuSystem’s rivals have a beta of 0.97, indicating that their average stock price is 3% less volatile than the S&P 500.
Summary
InfuSystem beats its rivals on 9 of the 13 factors compared.
About InfuSystem
InfuSystem Holdings, Inc. provides infusion pumps, related medical equipment and support services to healthcare providers and patients. Its products are used in settings such as hospitals, clinics and patients’ homes, including for oncology and pain-management therapies. The company operates through its Integrated Therapy Services and Durable Medical Equipment Services businesses. Its offerings include infusion pump rentals and sales, equipment management, biomedical services, clinical support and related supplies.
Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.
